User login
Key clinical point: Adding carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide improved long-term event-free survival (EFS) along with a manageable safety profile in patients with triple-negative breast cancer (TNBC).
Major finding: Patients receiving carboplatin+veliparib+paclitaxel vs. paclitaxel showed significant improvements in EFS (hazard ratio [HR] 0.63; P = .02), whereas EFS was not significntly different among patients assigned to carboplatin+veliparib+paclitaxel vs. carboplatin+paclitaxel (HR 1.12; P = .62). Rates of treatment-emergent and post-treatment-emergent adverse events and secondary malignancies were similar across treatment groups.
Study details: Findings are based on the 4.5-year follow-up data from the phase 3 BrighTNess trial including 634 patients with stage II-III TNBC who were randomly assigned to receive carboplatin+veliparib, carboplatin+veliparib placebo, or carboplatin placebo+veliparib placebo, all in combination with paclitaxel.
Disclosures: This study was supported by AbbVie. Some authors declared serving on the advisory board and speaker’s bureau or receiving travel funds, writing support, honoraria, research funds, and consulting fees from several sources including AbbVie. D Maag declared being an employee or stockholder of AbbVie.
Source: Geyer CE Jr et al. Ann Oncol. 2022 (Jan 27). Doi: 10.1016/j.annonc.2022.01.009.
Key clinical point: Adding carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide improved long-term event-free survival (EFS) along with a manageable safety profile in patients with triple-negative breast cancer (TNBC).
Major finding: Patients receiving carboplatin+veliparib+paclitaxel vs. paclitaxel showed significant improvements in EFS (hazard ratio [HR] 0.63; P = .02), whereas EFS was not significntly different among patients assigned to carboplatin+veliparib+paclitaxel vs. carboplatin+paclitaxel (HR 1.12; P = .62). Rates of treatment-emergent and post-treatment-emergent adverse events and secondary malignancies were similar across treatment groups.
Study details: Findings are based on the 4.5-year follow-up data from the phase 3 BrighTNess trial including 634 patients with stage II-III TNBC who were randomly assigned to receive carboplatin+veliparib, carboplatin+veliparib placebo, or carboplatin placebo+veliparib placebo, all in combination with paclitaxel.
Disclosures: This study was supported by AbbVie. Some authors declared serving on the advisory board and speaker’s bureau or receiving travel funds, writing support, honoraria, research funds, and consulting fees from several sources including AbbVie. D Maag declared being an employee or stockholder of AbbVie.
Source: Geyer CE Jr et al. Ann Oncol. 2022 (Jan 27). Doi: 10.1016/j.annonc.2022.01.009.
Key clinical point: Adding carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide improved long-term event-free survival (EFS) along with a manageable safety profile in patients with triple-negative breast cancer (TNBC).
Major finding: Patients receiving carboplatin+veliparib+paclitaxel vs. paclitaxel showed significant improvements in EFS (hazard ratio [HR] 0.63; P = .02), whereas EFS was not significntly different among patients assigned to carboplatin+veliparib+paclitaxel vs. carboplatin+paclitaxel (HR 1.12; P = .62). Rates of treatment-emergent and post-treatment-emergent adverse events and secondary malignancies were similar across treatment groups.
Study details: Findings are based on the 4.5-year follow-up data from the phase 3 BrighTNess trial including 634 patients with stage II-III TNBC who were randomly assigned to receive carboplatin+veliparib, carboplatin+veliparib placebo, or carboplatin placebo+veliparib placebo, all in combination with paclitaxel.
Disclosures: This study was supported by AbbVie. Some authors declared serving on the advisory board and speaker’s bureau or receiving travel funds, writing support, honoraria, research funds, and consulting fees from several sources including AbbVie. D Maag declared being an employee or stockholder of AbbVie.
Source: Geyer CE Jr et al. Ann Oncol. 2022 (Jan 27). Doi: 10.1016/j.annonc.2022.01.009.